- Home
- NAMS vs TMDX Comparison
NAMS vs TMDX Comparison
Compare NAMS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- TMDX
- Stock Information
- Founded
- NAMS 2019
- TMDX 1998
- Country
- NAMS Netherlands
- TMDX United States
- Employees
- NAMS N/A
- TMDX N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NAMS Health Care
- TMDX Health Care
- Exchange
- NAMS Nasdaq
- TMDX Nasdaq
- Market Cap
- NAMS 2.5B
- TMDX 2.3B
- IPO Year
- NAMS N/A
- TMDX 2019
- Fundamental
- Price
- NAMS $17.96
- TMDX $123.56
- Analyst Decision
- NAMS Strong Buy
- TMDX Buy
- Analyst Count
- NAMS 8
- TMDX 10
- Target Price
- NAMS $42.88
- TMDX $127.33
- AVG Volume (30 Days)
- NAMS 893.6K
- TMDX 830.9K
- Earning Date
- NAMS 08-06-2025
- TMDX 07-30-2025
- Dividend Yield
- NAMS N/A
- TMDX N/A
- EPS Growth
- NAMS N/A
- TMDX N/A
- EPS
- NAMS N/A
- TMDX 1.41
- Revenue
- NAMS $47,140,000.00
- TMDX $488,227,000.00
- Revenue This Year
- NAMS N/A
- TMDX $34.07
- Revenue Next Year
- NAMS N/A
- TMDX $20.76
- P/E Ratio
- NAMS N/A
- TMDX $87.63
- Revenue Growth
- NAMS 586.97
- TMDX 64.43
- 52 Week Low
- NAMS $14.06
- TMDX $55.00
- 52 Week High
- NAMS $27.29
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- NAMS 42.30
- TMDX 45.61
- Support Level
- NAMS $20.06
- TMDX $139.31
- Resistance Level
- NAMS $21.91
- TMDX $145.50
- Average True Range (ATR)
- NAMS 1.41
- TMDX 5.88
- MACD
- NAMS -0.20
- TMDX -2.71
- Stochastic Oscillator
- NAMS 4.45
- TMDX 12.94
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.